Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration yesterday approved the second tumor-agnostic precision oncology drug targeting NTRK gene fusions, called Vitrakvi (larotrectinib).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.